(Q53579925)

15 May 2018

title

Characterization of the expression and activation of the epidermal growth factor receptor in squamous cell carcinoma of the skin. (English)

1 reference

15 May 2018

author name string

Fogarty GB

1

1 reference

15 May 2018

Conus NM

2

1 reference

15 May 2018

Chu J

3

1 reference

15 May 2018

McArthur G

4

1 reference

15 May 2018

language of work or name

English

0 references

publication date

1 January 2007

1 reference

15 May 2018

British Journal of Dermatology

published in

1 reference

15 May 2018

volume

156

1 reference

15 May 2018

issue

1

1 reference

15 May 2018

page(s)

92-98

1 reference

15 May 2018

Comparison of Epidermal Growth Factor Binding and Receptor Distribution in Normal Human Epidermis and Epidermal Appendages

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Association of EGF receptor expression with proliferating cells and of ras p21 expression with differentiating cells in various skin tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Epidermal growth factor receptor overexpression and genetic aberrations in metastatic squamous-cell carcinoma of the skin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

EGFR blockade with ZD1839 ("Iressa") potentiates the antitumor effects of single and multiple fractions of ionizing radiation in human A431 squamous cell carcinoma. Epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Pharmacodynamic studies of the epidermal growth factor receptor inhibitor ZD1839 in skin from cancer patients: histopathologic and molecular consequences of receptor inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

The epidermal growth factor receptor mediates radioresistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Epidermal growth factor receptors in human epidermal tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Expression of EGF receptor, involucrin, and cytokeratins in basal cell carcinomas and squamous cell carcinomas of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Light microscopic autoradiographical analysis of [125I]epidermal growth factor binding in basal cell epithelioma and squamous cell carcinoma of the skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Coexpression patterns of EGFR, HER2, HER3 and HER4 in non-melanoma skin cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2133.2006.07603.X

10.1111/J.1365-2133.2006.07603.X

21 January 2018

Identifiers

DOI

1 reference

15 May 2018

1 reference

15 May 2018